This study in Experimental & Molecular Medicine investigates NGS-enabled phage display analysis. The authors show that sequencing-based screening identifies a broader and more diverse set of functional antibody clones than conventional colony screening methods.
In Nature Machine Intelligence, researchers present a framework for antibody and VHH nativeness. AbNatiV enables nativeness scoring and humanization guidance, supporting hit selection while retaining binding and stability, including an automated nanobody humanization pipeline.
Published on ScienceDirect, this paper analyses machine-learning approaches to antibody–antigen binding. It evaluates datasets and early ML methods for predicting antibody specificity directly from sequence, outlining key limitations and opportunities for scalable, sequence-based binding prediction.
A recent bioRxiv preprint examines structure-aware antibody language models. IgBlend combines antibody sequences with 3D structural coordinates, improving sequence recovery, CDR editing and inverse folding, with model likelihoods correlating with experimental binding affinity.
External research in Briefings in Bioinformatics explores antibody language models. This study introduces BALM and BALMFold, showing how large-scale antibody sequence models enable accurate antigen-binding and full atomic structure prediction, outperforming established structure-prediction methods.
Read about bypassing classical in vitro antibody screening in Nucleic Acids Research. This study shows how combining display technologies with next-generation sequencing enables in silico candidate selection, revealing high-affinity antibodies missed by conventional screening workflows.
We explain how VHHs – small format single-domain antibody fragments – have a range of unique properties that make them ideal for enhancing the therapeutic potential of conventional IgG antibodies.
VHH humanisation can be a challenge. Here, we compare two methods – safe-but-slow rational humanisation and fast-but-risky CDR grafting. We also explore the impact of synthetic versus immune-derived frameworks.
Small antibody building blocks: VHHs or “Nanobodies” are single domain antibodies about 1/10th the size of an IgG. Combined with their robust biophysical properties and high solubiltiy, the simplicity of these molecules…
Bi-specific antibodies (BsAbs) – antibodies that can recognise two different epitopes on either the same or different antigens – have been around for a long time. However, in the past few years we’ve seen a renaissance in the design and application of these molecules.
We explain how VHHs – small format single-domain antibody fragments – have a range of unique properties that make them ideal for enhancing the therapeutic potential of conventional IgG antibodies.
CIS display is a DNA-based in vitro display technology that enables the display and selection of peptides and proteins from extremely large libraries…